Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

From Insightful Science to Innovative Health: Strengthening Translational Capacity and Talent Interoperability in Vaccine and Biologic Research & innovation

Project description

Building global vaccine networks

The COVID-19 pandemic demonstrated how the management of such health threats requires close ties between research and industry, as well as strong local networks to produce and deliver vaccines. With this in mind, the EU-funded VISION project brings together partners from Serbia, Tunisia, Ukraine, and across Europe to boost skills in vaccine science through training and shared research. This includes high-tech mRNA tools. The project also aims to improve how factories scale up and deliver these products. By moving experts between regions and sharing data, VISION helps speed up discovery. The project’s goal is to help smaller nations become regional centres of excellence.

Objective

Following the COVID-19 pandemic, biologicals and vaccines became regarded as salient pillars for disease prevention and control. However, strengthening preparedness for and response to health emergencies request more commitment and intersectoral cooperation between academia and industry to set up efficient strategies against diseases, whether through surveillance, detection, diagnosis, prevention, or treatment. VISION (Vaccine & bIologics reSearch & innovatION) intends to implement an intensive intersectoral and bidirectional knowledge/know-how transfer programs in order to reinforce vaccine and biologics development capacities with manufacturing, upscaling, or delivery capabilities among a consortium with Institut Pasteur de Tunis (Tunisia), Darnitsa (Ukraine), Torlak Institute (Serbia) and Connect’innov (Tunisia) as academic (AC) & non-academic (NA) widening members; Institut Pasteur (France) and Center for Genomic Regulation (Spain) as academic research non widening (NW) organizations, Ciloa (France), ACTG-CRO (France), M4Health (Germany) and iBET (Portugal) as NW&NA partners. VISION comes as a critical lever for R&I ecosystem feeding post-pandemic needs and matches the WHO mRNA Transfer initiative aiming to enhance widening production capacities and help achieving a comprehensive health coverage towards Sustainable Development Goals. VISION will in fine streamline the discovery, testing and production of biologics and vaccine candidates including mRNA-based technologies. VISION's main objectives are threefold: (i) endow Widening Talents with advanced knowledge and skills in Vaccine and Biologics Development, (ii) promote more impactful collaboration through training and mobility between AC and NA sectors towards an efficient high-performance translational R&I environment with an Open Science pillar, and (iii) ambition to make widening members a regional flagship for excellence in innovative research with increased biobusiness and entrepreneurship capacity and openness to the socio-economic sector.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-WIDERA-2022-TALENTS-03

See all projects funded under this call

Coordinator

INSTITUT PASTEUR DE TUNIS
Net EU contribution
€ 1 719 791,25
Total cost
€ 1 719 791,25

Participants (10)